key: cord-0905170-036vbmka
authors: Filippini, Alida; Bnà, Claudio; Bellosta, Raffaello; Bazzani, Roberto; Luzzani, Luca; Pegorer, Matteo Alberto; Zandalasini, Matteo; Baldon, Michela; Codazzi, Manuela; Sabatini, Tony
title: COVID-19 acute respiratory distress syndrome: can iloprost have a role for the treatment?
date: 2021-01-30
journal: Respir Med Case Rep
DOI: 10.1016/j.rmcr.2021.101358
sha: acf1acb36739f42e2388dc0e6e0f4ba738bd407a
doc_id: 905170
cord_uid: 036vbmka

Pulmonary infection of 2019-nCoV can frequently induce acute respiratory distress syndrome (ARDS) with partial pressure of arterial oxygen/fraction of inspired oxygen ratio (pO2/FiO2) of less than 300 mmHg. Moreover, it can be complicated with cardiac injury or arrhythmia, microvascular and large-vessel thrombosis. We describe a case of a patient with COVID19-ARDS and concomitant critical ischemia of the limbs. Iloprost treatment, an analogue of a prostacyclin PGI2, was started for residual left forefoot ischemia after surgical thromboembolectomy. Unexpectedly, we documented improvement of respiratory performance and lung high resolution computed tomography (HRCT) showed significant regression of the diffuse pulmonary ground-glass opacity. The hypothetical mechanism is that iloprost can enhance perfusion preferentially to well-ventilated lung regions, reduce pressures of peripheral pulmonary vessels and induce reduction of lung interstitial edema. In addition, iloprost antithrombotic effect, endothelial damage repairing and neo-angiogenesis activity could play a relevant role.

Novel coronavirus 2019-nCoV infection cases are confirmed in multiple countries and can frequently induce severe acute respiratory syndrome with partial pressure of arterial oxygen/fraction of inspired oxygen ratio (pO2/FiO2) of less than 150 mmHg [1] .

The chest Computer Tomography showed bilateral lung infiltrates with rapidly involving of more than 75% of the pulmonary parenchyma and are due to acute inflammation of pulmonary tissue and alveolar space. COVID-19 infection is frequently complicated with pulmonary embolism, arterial ischemia and venous thrombosis of limbs and myocarditis or arrhythmia. Some clinical study documented improvement of gas exchange in ARDS with inhaled iloprost [2, 3, 4, 5] .

This report describes the use of iloprost in the treatment of a patient with bilateral critical tibial arteries ischemia and COVID-19 ARDS, and unexpectedly improvement of pulmonary performance.

A 66 years old caucasian male presented to our Emergency Department for bilateral lower limbs pain, numbness and cyanosis of left foot. Moreover the patient was complaining cough, fever and dyspnea for the last two weeks. Past medical history was silent. He did not smoke tobacco or use alcohol. The patient was in severe respiratory distress and vital signs were: temperature 38.6°C, blood pressure 104/64 mm Hg, pulse 103 bpm, respiratory rate 30 breaths per minute and oxygen pulse oximetry 84% on room air. Lung examination revealed bilateral basal crackles. The arterial blood gas showed pH 7.48, pCO 2 24mmHg and pO 2 53 mmHg, PaO 2 /FiO 2 250mmHg, lactate 8. The day after, SpO 2 rised to 99% and oxygen supplementation was switch to Venturi-mask FiO 2 60% at 15 L/min, and after the iloprost infusion, FiO 2 was progressively reduced to 28% at 4 L/m. Blood-gas control documented PO 2 /FiO 2 266 mmHg. At the third day of treatment the bilateral lower-lobe rales were no longer present. The oxygen therapy was switched to nasal cannulas 2 L/min and then was discontinued. Blood gas test showed pH 7.47, pCO 2 41mmHg and pO 2 62 mmHg, sO2 94% PaO 2 /FiO 2 295 mmHg, lactate 1.5 mmol/l. There was a reduction value of PCR (28.5 mg/L), LDH (317 U per liter), D-dimer (1180 ng/ml), IL6 (13.7 pg/ml).

A control chest-HRCT showed a significant regression of the diffuse ground-glass with higher percentage of areated areas, and some bilateral consolidation with air-bronchogram and bronchiolectasis, more represented in peripheral areas of the lungs. (Fig. 2 a-b) Iloprost was continued for the critical ischemia, and after seven infusion remained slight cyanosis of the left foot.

ARDS is frequently the clinical presentation of COVID-19 pneumonia infection. In our case, the patient showed the acute onset of respiratory failure, bilateral infiltrates on chest radiograph and CT, hypoxemia with PaO 2 /FiO 2 ratio ≤200 mmHg. Clinical trials have focused on the role of ventilation strategies as invasive or noninvasive ventilation devices and prone positioning [1, 6] , surfactant [7] , nitric oxide [8] , antiviral, corticosteroids and antibiotic therapy. It's known that the immune response plays a profound role in COVID-19 infection and development of ARDS. The initial inflammatory alveolar process is induced by the binding of microbial products or cell injuryassociated endogenous molecules to pattern recognition receptors. Alveolar macrophage and neutrophil extracellular traps are activated, leukocytes and erythrocytes are recruited in the sites of injury and partake in the production of bioactive mediators including protease, phospholipids, J o u r n a l P r e -p r o o f eicosanoids and proinflammatory-regulated cytokines that increase the inflammatory burden within the lung [6, 7, 8] . Increased permeability of the microvascular barrier results in the extravascular accumulation of protein-rich edema fluid into the alveolar space and, subsequently, hypoxemia due to impaired gas exchange.

Lungs autopsy of patient with COVID-19 infection reveled diffuse alveolar damage, hemorrhage and histiocytic desquamation, hyaline membrane development, interstitial edema and fibrin with alveolar macrophages accumulation and thrombi occluding small lung vessels [9] .

In our case we used iloprost for the treatment of residual critical ischemia of limb and after the first infusion we documented improvement of respiratory performance. Iloprost is an analogue of epoprostenol, a prostaciclin (PGI2), mainly produced in the vascular endothelium, with numerous properties as inhibition of platelet aggregation, vasodilatation, antiinflammatory and protective effects on endothelial barrier dysfunction [10, 11] . Iloprost is used in Buerger's disease, in forms of peripheral ischemia and Raynaud's phenomenon and for pulmonary arterial hypertension. In animal models, iloprost improves endothelial barrier function and reduces the signs of pulmonary edema, and the sequestration of leukocytes and platelets [10, 11, 12] . PGI2 has been shown to have antiinflammatory functions attributed to the cyclooxygenase-2 (COX-2) system [13, 14, 15] and the involvement of lipoxin A4 [16] and Ras-related protein 1 (RAP-1) [17] . The infusion of iloprost, in patients with systemic sclerosis reduces T cells in the peripheral blood, especially TNFα producing T cells, and some studies documented that iloprost reduces TNFα transcriptional activity and decreases TNFα mRNA stability so that it's reduces both the amount of TNFα positive T cells and the secretion TNFα after an antigenic stimulus [18, 19, 20] .

The acute respiratory distress syndrome

Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (th Thllo trial): a prospective, randomized, multicenter phase II study

Effect of inhaled iloprost on gas exchange in inhalation injury

Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS)

Iloprost improves gas exchange in patients with pulmonary hypertension and ARDS

Prone positioning improves survival in severe ARDS: a pathophysiologic review and individual patient meta-analysis

Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. The New England journal of medicine

Inhaled Nitric Oxide in ARDS Study Group. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. The Lancet infectious disease

Iloprost modulates the immune response in systemic sclerosis

Iloprost improves endothelial barrier function in lipopolysaccharide-induced lung injury

Iloprost attenuates trauma-related pulmonary sequestration of leucocytes and platelets

Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells

Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness

Role of prostaglandin I2 in airway remodeling induced by repeated allergen challenge in mice

Protective role of cyclooxygenase (COX)-2 in experimental lung injury: evidence of a lipoxin A4-mediated effect

Rap1 mediates protective effects of iloprost against ventilator-induced lung injury

Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms

Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells